arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Pelthos Therapeutics Inc.

PTHS

$9.12 ▼ -1.19 (-11.54%) at close

5 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Pelthos Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $17.2M

Dividend Yield —

Revenue Growth —

Op. Margin -193.1%

ROIC -71.3% ↘

FCF / Share $-12.07 ↘

Trailing P/E —

Price / Book 0.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$16.80M

— —

Net Income Profit after all expenses

$-43.32M

↓ -444.6% —

FCF / Share Free cash flow per share

$-12.07

↓ -16.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	-61.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	2.3% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-444.6% Weak ↓ Weak Declining Year-over-year change in net income	-7.8% Weak Weak Year-over-year change in net income	-200.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-16.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	-35.2% Weak Weak Year-over-year change in free cash flow	78.7% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Operating Margin (%) (%)	-193.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1387%)	—	—	—	—
Effective Tax Rate (%) (%)	14.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	-257.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2249%)	—	—	—	—
FCF Margin (%) (%)	-135.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.52x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.13x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-71.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	279.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	84.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	49.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-24.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-553.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-7119.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-4209.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-111.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-843%)	293.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1854%)	114.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+664%)	66.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+342%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Interest Coverage (x)	-1706.84x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	—	-477.54x Weak Weak Operating income divided by interest expense Optimal: > 5x	-17.09x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-17.97M	$-513.00K	$-100.00K	$-100.00K	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	$8.93	$0.00	—	—	—
Basic EPS, GAAP (USD)	$-23.04	$-14.27	$57.80	$56.50	—
Free Cash Flow per Share (USD)	$-12.07	$-10.39	$-7.69	$-36.00	—
Book Value per Share (USD)	$12.02	$-4.45	$-16.46	$-31.22	—
Tangible Book Value per Share (USD)	$4.39	$-4.45	$-16.46	$-31.22	—
Basic Weighted Avg Shares (shares)	1.88M	557,447	127,654	43,531	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$27.42M	$-2.71M	$-6.44M	$-3.71M	—
Total Equity (USD)	$38.88M	$-2.71M	$-6.44M	$-3.71M	$-3.68M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$16.80M	$0.00	—	—	—
Depreciation Expense (USD)	$729.00K	$0.00	—	—	—
Net Income, GAAP (USD)	$-43.32M	$-7.96M	$-7.38M	$-2.46M	—
Operating Cash Flow (USD)	$-22.59M	$-5.79M	$-981.03K	$-1.57M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 17 quarters

Pelthos Therapeutics Inc.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PTHS with peers